Literature DB >> 20829508

The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk.

Melissa C Smart-Halajko1, Marius R Robciuc, Jackie A Cooper, Matti Jauhiainen, Meena Kumari, Mika Kivimaki, Kay-Tee Khaw, S Matthijs Boekholdt, Nicholas J Wareham, Tom R Gaunt, Ian N Day, Peter S Braund, Christopher P Nelson, Alistair S Hall, Nilesh J Samani, Steve E Humphries, Christian Ehnholm, Philippa J Talmud.   

Abstract

OBJECTIVE: To investigate the relationship between angiopoietin-like protein 4 (Angptl4) levels, coronary heart disease (CHD) biomarkers, and ANGPTL4 variants. METHODS AND
RESULTS: Plasma Angptl4 was quantified in 666 subjects of the Northwick Park Heart Study II using a validated ELISA. Seven ANGPTL4 single-nucleotide polymorphisms were genotyped, and CHD biomarkers were assessed in the whole cohort (N=2775). Weighted mean±SD plasma Angptl4 levels were 10.0±11.0 ng/mL. Plasma Angptl4 concentration correlated positively with age (r=0.15, P<0.001) and body fat mass (r=0.19, P=0.003) but negatively with plasma high-density lipoprotein cholesterol (r=-0.13, P=0.01). No correlation with triglycerides (TGs) was observed. T266M was independently associated with plasma Angptl4 levels (P<0.001) but was not associated with TGs or CHD risk in the meta-analysis of 5 studies (4061 cases/15 395 controls). E40K showed no independent association with plasma Angptl4 levels. In human embryonic kidney 293 and human hepatoma 7 cells compared with wild type, E40K and T266M showed significantly altered synthesis and secretion, respectively.
CONCLUSIONS: Circulating Angptl4 levels may not influence TG levels or CHD risk for the following reasons: (1) Angptl4 levels were not correlated with TGs; (2) T266M, although associated with Angptl4 levels, showed no association with plasma TGs; and (3) TG-lowering E40K did not influence Angptl4 levels. These results provide new insights into the role of Angptl4 in TG metabolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20829508      PMCID: PMC3319296          DOI: 10.1161/ATVBAHA.110.212209

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  22 in total

1.  EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer.

Authors:  N Day; S Oakes; R Luben; K T Khaw; S Bingham; A Welch; N Wareham
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men.

Authors:  Philippa J Talmud; Emma Hawe; George J Miller; Steve E Humphries
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-11-01       Impact factor: 8.311

4.  Response of adipose tissue lipoprotein lipase to the cephalic phase of insulin secretion.

Authors:  F Picard; N Naïmi; D Richard; Y Deshaies
Journal:  Diabetes       Date:  1999-03       Impact factor: 9.461

Review 5.  GPIHBP1, a GPI-anchored protein required for the lipolytic processing of triglyceride-rich lipoproteins.

Authors:  Anne P Beigneux; Brandon S J Davies; André Bensadoun; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2008-10-14       Impact factor: 5.922

6.  Angiopoietin-like protein 4: development, analytical characterization, and clinical testing of a new ELISA.

Authors:  D Stejskal; M Karpísek; H Reutová; V Humenanská; M Petzel; P Kusnierová; I Vareka; R Vareková; P Stejskal
Journal:  Gen Physiol Biophys       Date:  2008-03       Impact factor: 1.512

Review 7.  Nutritional regulation of lipoprotein lipase.

Authors:  T Olivecrona; M Bergö; M Hultin; G Olivecrona
Journal:  Can J Cardiol       Date:  1995-10       Impact factor: 5.223

8.  GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4.

Authors:  William K Sonnenburg; Daiguan Yu; E-Chiang Lee; Wei Xiong; Gennady Gololobov; Billie Key; Jason Gay; Nat Wilganowski; Yi Hu; Sharon Zhao; Matthias Schneider; Zhi-Ming Ding; Brian P Zambrowicz; Greg Landes; David R Powell; Urvi Desai
Journal:  J Lipid Res       Date:  2009-06-21       Impact factor: 5.922

9.  Health inequalities among British civil servants: the Whitehall II study.

Authors:  M G Marmot; G D Smith; S Stansfeld; C Patel; F North; J Head; I White; E Brunner; A Feeney
Journal:  Lancet       Date:  1991-06-08       Impact factor: 79.321

10.  Genetic variation in ANGPTL4 provides insights into protein processing and function.

Authors:  Wu Yin; Stefano Romeo; Shurong Chang; Nick V Grishin; Helen H Hobbs; Jonathan C Cohen
Journal:  J Biol Chem       Date:  2009-03-07       Impact factor: 5.157

View more
  32 in total

1.  AKT3, ANGPTL4, eNOS3, and VEGFA associations with high altitude sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau.

Authors:  Norman E Buroker; Xue-Han Ning; Zhao-Nian Zhou; Kui Li; Wei-Jun Cen; Xiu-Feng Wu; Wei-Zhong Zhu; C Ronald Scott; Shi-Han Chen
Journal:  Int J Hematol       Date:  2012-06-24       Impact factor: 2.490

2.  Fatty acids bind tightly to the N-terminal domain of angiopoietin-like protein 4 and modulate its interaction with lipoprotein lipase.

Authors:  Terje Robal; Mikael Larsson; Miina Martin; Gunilla Olivecrona; Aivar Lookene
Journal:  J Biol Chem       Date:  2012-07-07       Impact factor: 5.157

Review 3.  ANGPTL4 in Metabolic and Cardiovascular Disease.

Authors:  Binod Aryal; Nathan L Price; Yajaira Suarez; Carlos Fernández-Hernando
Journal:  Trends Mol Med       Date:  2019-06-21       Impact factor: 11.951

4.  Upregulation of podocyte-secreted angiopoietin-like-4 in diabetic nephropathy.

Authors:  Jing Ma; Xiao Chen; Jian-Si Li; Lei Peng; Shi-Yao Wei; Shi-Lei Zhao; Tong Li; Dan Zhu; Yi-Xin He; Qiu-Ju Wei; Bing Li
Journal:  Endocrine       Date:  2014-11-26       Impact factor: 3.633

5.  Angiopoietin-like 4 Modifies the Interactions between Lipoprotein Lipase and Its Endothelial Cell Transporter GPIHBP1.

Authors:  Xun Chi; Shwetha K Shetty; Hannah W Shows; Alexander J Hjelmaas; Emily K Malcolm; Brandon S J Davies
Journal:  J Biol Chem       Date:  2015-03-25       Impact factor: 5.157

6.  Do ANGPTL-4 and galectin-3 reflect the severity of coronary artery disease?

Authors:  Luxitaa Goenka; Melvin George; Vishakha Singh; Amrita Jena; Deepika Seshadri; Vasanth Karunakaran; Dhandapani Vellala Elumalai; Jamuna Rani; Ilango Kaliappan
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-08-10

7.  Assessing mechanisms of GPIHBP1 and lipoprotein lipase movement across endothelial cells.

Authors:  Brandon S J Davies; Chris N Goulbourne; Richard H Barnes; Kirsten A Turlo; Peter Gin; Sue Vaughan; David J Vaux; André Bensadoun; Anne P Beigneux; Loren G Fong; Stephen G Young
Journal:  J Lipid Res       Date:  2012-09-24       Impact factor: 5.922

8.  Angiopoietin-like protein 4 inhibition of lipoprotein lipase: evidence for reversible complex formation.

Authors:  Michael J Lafferty; Kira C Bradford; Dorothy A Erie; Saskia B Neher
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

9.  Angiopoietin-like 4 deficiency upregulates macrophage function through the dysregulation of cell-intrinsic fatty acid metabolism.

Authors:  Shizhen Ding; Dandan Wu; Quotao Lu; Li Qian; Yanbing Ding; George Liu; Xiaoqin Jia; Yu Zhang; Weiming Xiao; Weijuan Gong
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 6.166

10.  Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes.

Authors:  Wieneke Dijk; Anne P Beigneux; Mikael Larsson; André Bensadoun; Stephen G Young; Sander Kersten
Journal:  J Lipid Res       Date:  2016-03-31       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.